MDCLF
MedinCell S.A.·Healthcare
34.39
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $6.9852W H: $34.39
MDCLF NEWS
businesswire.com
Feb 24
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments (the "Company"), today announced its participation at the TD Cowen 46th Annual Healthcare Conference, which will take place March 2-4, 2026 in Boston. The Company will present on Tuesday, March 3, 2026, at 1:50pm ET. Investor meetings with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, may.
businesswire.com
Jan 28
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results: About UZEDY® 2025 net sales reached $191 million, including $55 million in the fourth quarter Teva's initial 2026 net sales outlook is in the range of $250 - $280 million Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105.
